Laboratory Corp (LH) Gets a Buy Rating from Morgan Stanley

In a report released today, Ricky Goldwasser from Morgan Stanley maintained a Buy rating on Laboratory Corp (LH), with a price target of $180. The company’s shares closed on Friday at $145.64, close to its 52-week low of $142.40.

According to, Goldwasser is a 3-star analyst with an average return of 3.0% and a 56.2% success rate. Goldwasser covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, Quest Diagnostics Inc, and Charles River Labs.

Currently, the analyst consensus on Laboratory Corp is a Moderate Buy with an average price target of $170.50, representing a 17.1% upside. In a report issued on November 30, Piper Jaffray also maintained a Buy rating on the stock with a $177 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $190.36 and a one-year low of $142.40. Currently, Laboratory Corp has an average volume of 824.1K.

Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. Last month, Kerrii Anderson, a Director at LH sold 3,700 shares for a total of $604,136.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.